New Results
The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells, decrease production of proinflammatory cytokines, and VIP levels are associated with survival in severe Covid-19 patients
View ORCID ProfileJairo R. Temerozo, Carolina Q. Sacramento, Natalia Fintelman-Rodrigues, Camila R. R. Pão, Caroline S. de Freitas, Suelen da Silva Gomes Dias, André C. Ferreira, Mayara Mattos, Vinicius Cardoso Soares, Lívia Teixeira, Isaclaudia G. de Azevedo-Quintanilha, Pedro Kurtz, Fernando A. Bozza, Patrícia T. Bozza, Thiago Moreno L. Souza, Dumith Chequer Bou-Habib
doi: https://doi.org/10.1101/2020.07.25.220806
Jairo R. Temerozo
1Laboratory on Thymus Research, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
8National Institute for Science and Technology on Neuroimmunomodulation, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
Carolina Q. Sacramento
2Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
3National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil
Natalia Fintelman-Rodrigues
2Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
3National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil
Camila R. R. Pão
2Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
Caroline S. de Freitas
2Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
3National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil
Suelen da Silva Gomes Dias
2Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
André C. Ferreira
2Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
3National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil
4Universidade Iguaçu, Nova Iguaçu, RJ, Brazil
Mayara Mattos
2Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
3National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil
Vinicius Cardoso Soares
2Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
Lívia Teixeira
2Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
Isaclaudia G. de Azevedo-Quintanilha
2Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
Pedro Kurtz
5Paulo Niemeyer State Brain Institute, Rio de Janeiro, RJ, Brazil
6Instituto D’or de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil
Fernando A. Bozza
6Instituto D’or de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil
7Instituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro, RJ, Brazil
Patrícia T. Bozza
2Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
Thiago Moreno L. Souza
2Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
3National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ, Brazil
Dumith Chequer Bou-Habib
1Laboratory on Thymus Research, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
8National Institute for Science and Technology on Neuroimmunomodulation, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil
Posted July 27, 2020.
The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells, decrease production of proinflammatory cytokines, and VIP levels are associated with survival in severe Covid-19 patients
Jairo R. Temerozo, Carolina Q. Sacramento, Natalia Fintelman-Rodrigues, Camila R. R. Pão, Caroline S. de Freitas, Suelen da Silva Gomes Dias, André C. Ferreira, Mayara Mattos, Vinicius Cardoso Soares, Lívia Teixeira, Isaclaudia G. de Azevedo-Quintanilha, Pedro Kurtz, Fernando A. Bozza, Patrícia T. Bozza, Thiago Moreno L. Souza, Dumith Chequer Bou-Habib
bioRxiv 2020.07.25.220806; doi: https://doi.org/10.1101/2020.07.25.220806
The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells, decrease production of proinflammatory cytokines, and VIP levels are associated with survival in severe Covid-19 patients
Jairo R. Temerozo, Carolina Q. Sacramento, Natalia Fintelman-Rodrigues, Camila R. R. Pão, Caroline S. de Freitas, Suelen da Silva Gomes Dias, André C. Ferreira, Mayara Mattos, Vinicius Cardoso Soares, Lívia Teixeira, Isaclaudia G. de Azevedo-Quintanilha, Pedro Kurtz, Fernando A. Bozza, Patrícia T. Bozza, Thiago Moreno L. Souza, Dumith Chequer Bou-Habib
bioRxiv 2020.07.25.220806; doi: https://doi.org/10.1101/2020.07.25.220806
Subject Area
Subject Areas
- Biochemistry (11730)
- Bioengineering (8743)
- Bioinformatics (29179)
- Biophysics (14964)
- Cancer Biology (12080)
- Cell Biology (17399)
- Clinical Trials (138)
- Developmental Biology (9417)
- Ecology (14174)
- Epidemiology (2067)
- Evolutionary Biology (18294)
- Genetics (12233)
- Genomics (16791)
- Immunology (11858)
- Microbiology (28051)
- Molecular Biology (11575)
- Neuroscience (60919)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4955)
- Plant Biology (10422)
- Synthetic Biology (2881)
- Systems Biology (7338)
- Zoology (1650)